Rare disease firm Rezolute's Q2 net loss widens

Reuters

Feb 13

Rare disease firm Rezolute's <a href="https://laohu8.com/S/QTWO">Q2</a> net loss widens

Overview

Rare disease company reported Q2 fiscal 2026 net loss of $22.8 mln, up from last year
R&D expenses rose to $14.3 mln due to increased clinical trial activities

Outlook

Rezolute to meet FDA by end of Q1 under Breakthrough Therapy Designation
Topline results for tumor HI study expected in H2 2026

Result Drivers

INCREASED R&D EXPENSES - R&D expenses rose due to increased clinical trial activities and employee-related costs, including severance benefits

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q2 EPS		-$0.22
Q2 Net Income		-$22.77 mln
Q2 Income From Operations		-$24.22 mln
Q2 Operating Expenses		$24.22 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Rezolute Inc is $5.00, about 48.4% above its February 11 closing price of $3.37

Press Release: ID:nGNXQJyWy

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2611563908"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2611563908\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2611563908?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-13 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2611563908","market":"us","top_or_hot":-1,"title":"Rare disease firm Rezolute's Q2 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rare disease firm Rezolute's <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens </title></head><body><p><span>Overview</span></p><ul><li><p>Rare disease company reported Q2 fiscal 2026 net loss of $22.8 mln, up from last year</p></li><li><p>R&amp;D expenses rose to $14.3 mln due to increased clinical trial activities</p></li></ul><p><span>Outlook</span></p><ul><li><p>Rezolute to meet FDA by end of Q1 under Breakthrough Therapy Designation</p></li><li><p>Topline results for tumor HI study expected in H2 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - R&amp;D expenses rose due to increased clinical trial activities and employee-related costs, including severance benefits</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.22</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$22.77 mln</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td></td><td><p>-$24.22 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$24.22 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Rezolute Inc is $5.00, about 48.4% above its February 11 closing price of $3.37</p></li></ul><p>Press Release: <span>ID:nGNXQJyWy</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Rare disease firm Rezolute's Q2 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRare disease firm Rezolute's Q2 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-13 05:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Rare disease firm Rezolute's <a href=\"https://laohu8.com/S/QTWO\">Q2</a> net loss widens </title></head><body><p><span>Overview</span></p><ul><li><p>Rare disease company reported Q2 fiscal 2026 net loss of $22.8 mln, up from last year</p></li><li><p>R&amp;D expenses rose to $14.3 mln due to increased clinical trial activities</p></li></ul><p><span>Outlook</span></p><ul><li><p>Rezolute to meet FDA by end of Q1 under Breakthrough Therapy Designation</p></li><li><p>Topline results for tumor HI study expected in H2 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>INCREASED R&amp;D EXPENSES - R&amp;D expenses rose due to increased clinical trial activities and employee-related costs, including severance benefits</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q2 EPS</p></td><td></td><td><p>-$0.22</p></td><td></td></tr><tr><td><p>Q2 Net Income</p></td><td></td><td><p>-$22.77 mln</p></td><td></td></tr><tr><td><p>Q2 Income From Operations</p></td><td></td><td><p>-$24.22 mln</p></td><td></td></tr><tr><td><p>Q2 Operating Expenses</p></td><td></td><td><p>$24.22 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Rezolute Inc is $5.00, about 48.4% above its February 11 closing price of $3.37</p></li></ul><p>Press Release: <span>ID:nGNXQJyWy</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z81G5:1","article_id":"2611563908","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2611563908","pubTimestamp":1770931713,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Rare disease firm Rezolute's Q2 net loss widensOverviewRare disease company reported Q2 fiscal 2026 net loss of $22.8 mln, up from last yearR&D expenses rose to $14.3 mln due to increased clinical tri","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","RZLT":"Rezolute, Inc."},"translate_title":"罕见病公司Rezolute第二季度净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RZLT":0.9},"content_text":"Rare disease firm Rezolute's Q2 net loss widens OverviewRare disease company reported Q2 fiscal 2026 net loss of $22.8 mln, up from last yearR&D expenses rose to $14.3 mln due to increased clinical trial activitiesOutlookRezolute to meet FDA by end of Q1 under Breakthrough Therapy DesignationTopline results for tumor HI study expected in H2 2026Result DriversINCREASED R&D EXPENSES - R&D expenses rose due to increased clinical trial activities and employee-related costs, including severance benefitsKey DetailsMetricBeat/MissActualConsensus EstimateQ2 EPS-$0.22Q2 Net Income-$22.77 mlnQ2 Income From Operations-$24.22 mlnQ2 Operating Expenses$24.22 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 4 \"hold\" and no \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Rezolute Inc is $5.00, about 48.4% above its February 11 closing price of $3.37Press Release: ID:nGNXQJyWyFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}